DJ Carvolix: ODDO BHF initiates coverage of Carvolix with an Outperform rating.
Affluent Medical Carvolix: ODDO BHF initiates coverage of Carvolix with an Outperform rating. 29-Jul-2026 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- PRESS RELEASE
ODDO BHF initiates coverage of Carvolix with an Outperform rating
Aix-en-Provence, July 29, 2026 - Carvolix (formerly Affluent Medical) (ISIN: FR0013333077 - Ticker: CVX), a French commercial and clinical-stage medical technology company specializing in the international development, industrialization and commercialization of breakthrough AI-driven mini-robots and biomimetic implants, today announces the initiation of coverage of its shares by ODDO BHF.
In its research report entitled "A multi-specialty interventional platform", published on 28 July 2026, ODDO BHF initiated coverage of Carvolix with an Outperform rating and a price target of EUR10.50, representing an upside potential of 89% compared with the closing share price on 28 July 2026.
This initiation further broadens the Company's equity research coverage and expands the analyst consensus, alongside Allinvest Securities, Kepler Cheuvreux, Portzamparc Groupe BNP Paribas and TP ICAP.
The recommendations, estimates, and price targets mentioned in this press release are those of ODDO BHF and reflect solely the analysis of that firm.
This press release does not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, securities in France, Europe, the United States or any other jurisdiction.
About Carvolix
Carvolix is a French medical technologies company, commercial and clinical stage, founded by Truffle Capital (also founder of the top European biotech company), that aims to become a global leader in the treatment of structural heart diseases and brain strokes, the world's leading causes of mortality and disability. According to the Truffle 10 MedTech Index, Carvolix ranks number one in Europe and number six worldwide. Carvolix develops novel AI and imaging driven mini robots that make complex procedures doable by interventional cardiologists, as well as biomimetic heart valves.
For more information: www.carvolix.eu
Contacts
CARVOLIX
SEITOSEI.ACTIFIN -
Sébastien LADET
Financial communication / Financial press relations Ghislaine GASPARETTO /
Jennifer JULLIA
CEO
+33 (0)6 85 36 76 81 / +33 (0)6 02 08 45 49
ghislaine.gasparetto@seitosei-actifin.com / jennifer.jullia@seitosei-actifin.com
investor@carvolix.eu
PRIMATICE - Media relations France
MC SERVICES AG - Media relations Europe Maximilian SCHUR / Julia BITTNER
Thomas ROBOREL de CLIMENS
+49 (0)211 529252 20 / +49 (0)211 529252 28 carvolix@mc-services.eu
+33 (0)6 78 12 97 95
thomasdeclimens@primatice.com
-----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file
File: Carvolix_PR_EN_coverage_Oddo
=------------------------------------------------------------------
Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext Ticker: AFME
AMF Category: Inside information / Other releases
EQS News ID: 2373822
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
2373822 29-Jul-2026 CET/CEST
Image link: https://nwr.eqs-cockpit.com/fncls2.ssx?application_id=2373822&application_name=news&site_id=dow_jones%7e%7e%7ebed8b539-0373-42bd-8d0e-f3efeec9bbed
(END) Dow Jones Newswires
July 29, 2026 11:45 ET (15:45 GMT)
